Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Medtronic
Accenture
Queensland Health
Express Scripts
Harvard Business School
AstraZeneca
Daiichi Sankyo
Fuji
Boehringer Ingelheim

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Stable polymorph of flibanserin
Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.
Inventor(s): Bombarda; Carlo (Chester, VA), Dubini; Enrica (Milan, IT), Ezhaya; Antoine (Milan, IT), Schneider, legal representative; Margarete (Ingelheim, DE), Schneider, deceased; Heinrich (Ingelheim, DE)
Assignee: Bidachem S.p.A. (Fornovo San Giovanna, IT)
Filing Date:Aug 01, 2002
Application Number:10/210,474
Claims:1. A process for preparing form A of flibanserin 1 having an endothermic maximum at about 161.degree. C. which occurs during thermal analysis using DSC, ##STR00003## said process comprising: (a) reacting a benzimidazolone 2 ##STR00004## wherein R denotes a suitable amino protecting group, with a piperazine 3 ##STR00005## wherein X is a leaving group selected from chlorine, bromine, iodine, methanesulphonate, trifluoromethanesulphonate and para-toluenesulphonate, in a suitable solvent selected from water, alcohols, mixtures of water with alcohols, polar aprotic solvents and mixtures of polar aprotic solvents with water, in the presence of a suitable base, and (b) cleaving the amino protecting group R under suitable cleaving conditions.

2. A process according to claim 1, wherein the reaction of 2 with 3 is conducted at a temperature of at least 50.degree. C.

3. A process according to claim 2, wherein heating is conducted for about 10 minutes to about 12 hours.

4. A process for preparing flibanserin 1 comprising form A having an endothermic maximum at about 161.degree. C. which occurs during thermal analysis using DSC, ##STR00006## said process comprising: (a) reacting a benzimidazolone 2 ##STR00007## wherein R denotes a suitable amino protecting group, with a piperazine 3 ##STR00008##

5. A process according to claim 4, wherein the reaction of 2 with 3 is conducted at a temperature of at least 50.degree. C.

6. A process according to claim 5, wherein heating is conducted for about 10 minutes to about 12 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
Federal Trade Commission
Johnson and Johnson
UBS
Cipla
Express Scripts
Queensland Health
Julphar
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot